Jazz Pharmaceuticals plc - 8-K Filing
Jazz Pharmaceuticals reports Q3 2026 revenue of $1.24B (+10% YoY) and raises full-year guidance following Actio Biosciences acquisition. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $JAZZ